Changes in Mf (A and B) CFA (C and D) prevalence at baseline, 1, 2 and 3 years after starting MDA. حسب Michael C. Payne (2664379)

الموضوعات:

Sentinel sites located within areas treated with MDA semiannually (solid red line) or annually (dashed blue line). حسب Michael C. Payne (2664379)

الموضوعات:

Directly observed antifilarial drug ingestion rates in semiannual and annual mass drug administration (MDA) areas. حسب Michael C. Payne (2664379)

الموضوعات:

Changes in circulating filarial antigen (CFA) prevalence and levels at years 1, 2, and 3 following the start of mass drug administration, with treatment given semiannually (2x/yr)... حسب Michael C. Payne (2664379)

الموضوعات:

Trends in overall global leukemia burden, 1990-2021. حسب Chengjun Hu (588206)

الموضوعات:

Projected global leukemia burden, 1990-2050. حسب Chengjun Hu (588206)

الموضوعات:

Map of the overall global burden of leukemia, 1990-2021. حسب Chengjun Hu (588206)

الموضوعات:

Project the global leukemia burden in patients younger and older than 20 years. حسب Chengjun Hu (588206)

الموضوعات:

Leukemia ASDR and SDI for 204 countries and territories in 2021. حسب Chengjun Hu (588206)

الموضوعات:

Map of the overall global leukemia burden status, 1990-2021. حسب Chengjun Hu (588206)

الموضوعات:

Frontier analysis based on SDI and age-standardized leukemia ASDR per 100,000 population from 1990 to 2021. حسب Chengjun Hu (588206)

الموضوعات:

Correlation between HDI and EAPC. حسب Chengjun Hu (588206)

الموضوعات:

Global leukemia incidence and EAPC, 1990-2021. حسب Chengjun Hu (588206)

الموضوعات:

Global and five SDI regions’ leukemia burden trends, 1990-2021. حسب Chengjun Hu (588206)

الموضوعات:

Global Distribution of the Number of Males and Females with Leukemia. حسب Chengjun Hu (588206)

الموضوعات:

Leukemia ASDR by SDI for 22 GBD regions from 1990 to 2021. حسب Chengjun Hu (588206)

الموضوعات:

Joinpoint regression analysis of global leukemia incidence in males and females from 1990 to 2021. حسب Chengjun Hu (588206)

الموضوعات:

Validation of genetic markers for risk of OA or knee OA for decrease in minJSW. حسب Mieke L. M. Bentvelzen (21594442)

"…The red line represents the significance threshold (<i>P < </i>5 × 10⁻⁸). …"

Flow chart of experimental protocol. حسب Eun-Seon Yang (19751340)

الموضوعات:

General characteristics and resting vital signs of the participants. حسب Eun-Seon Yang (19751340)

الموضوعات: